The Retina Channel Podcast

Dr. Brian Ballios from the University of Toronto and Toronto Western Hospital returns to The Retina Channel for a comprehensive update on inherited retinal diseases (IRDs). We discuss the evolving landscape of gene therapy, including long-term experience with RPE65 therapy and emerging treatments for IRDs including antisense oligonucleotides, optogenetics, new therapies for Stargardt disease, stem cell and photoreceptor replacement strategies, and the importance of natural history studies in designing future clinical trials. Brian was the second-ever guest on The Retina Channel back in 2017, making his return for Episode 98 nearly nine years later a particularly special one. A fascinating discussion about how far the field has come — and where IRD treatment may be heading next.

In this episode of The Retina Channel Podcast, Dr. Keyvan Koushan sits down with renowned retina specialist John Kitchens to discuss the rapidly evolving role of artificial intelligence in ophthalmology and medicine. Dr. Kitchens shares his practical experience using AI platforms such as ChatGPT, Claude, Gemini, and Perplexity, offering insights into how these tools can enhance clinical practice, education, research, communication, and everyday productivity. The conversation explores both the opportunities and limitations of AI, provides real-world examples of its use in ophthalmology, and offers a thoughtful look at how physicians can prepare for a future increasingly shaped by intelligent technologies. Whether you're an AI enthusiast or just beginning to explore these tools, this episode offers a practical and engaging perspective on one of the most important technological shifts in modern medicine.

In this episode of The Retina Channel Podcast, Dr. Jennifer Sun joins Dr. Keyvan Koushan to discuss the Phase 2 results of DRCR Retina Network Protocol AN evaluating tonabersat for diabetic macular edema. Dr. Sun reviews the rationale behind targeting connexin-43–mediated inflammatory pathways in DME, the key efficacy and safety findings from the study, and the potential implications of this novel oral therapy for future diabetic retinal disease management. The conversation also explores broader trends in DRCR clinical research and emerging treatment paradigms in diabetic eye disease.

In this episode of The Retina Channel Podcast, I sit down with Dr. Seong Joon Ahn from Hanyang University in South Korea to discuss a recent JAMA Ophthalmology study examining systemic drugs associated with underrecognized maculopathy. Using a novel two-step approach that integrates pharmacovigilance signal detection from the FDA Adverse Event Reporting System (FAERS) with nationwide health-claims data from South Korea, the study identifies several commonly used systemic medications— apixaban, paclitaxel, ibrutinib, fingolimod, and sildenafil—as being associated with an increased risk of maculopathy. We explore the study's methodology, key findings such as dose-response relationships, and the clinical implications for retina specialists and general ophthalmologists alike, particularly around patient counseling and the potential need for ocular monitoring in patients on these medications.   Kim J, Ahn SJ, Park J, Gower EW, Chung JE. Systemic drugs associated with maculopathy. JAMA Ophthalmol.2025;143(11):946-952. doi:10.1001/jamaophthalmol.2025.3612.